Skip to main content
Rize RecoveryThe Newsroom
Science & Medicine· Research Roundup

Semaglutide Cuts Heavy Drinking by 41%: What The Lancet RCT Means for Alcohol Use Disorder Treatment

A double-blind, placebo-controlled trial published May 2 positions GLP-1 receptor agonists as the most significant new pharmacological candidate for AUD in a generation.

ByThe Rize NewsroomMay 26, 20261 min readAlcohol

Semaglutide Cuts Heavy Drinking by 41%

The study: A randomized, double-blind, placebo-controlled trial published May 2, 2026 in The Lancet enrolled 108 adults with moderate-to-severe alcohol use disorder and comorbid obesity. Participants received once-weekly semaglutide 2.4 mg or placebo for 26 weeks; all participants were also offered standard cognitive behavioral therapy.

Primary results: Semaglutide was associated with a –41.1 percentage point reduction in heavy drinking days from baseline, versus –26.4 percentage points for placebo — a 14.7 pp advantage. Participants in the semaglutide arm also had larger decreases in total monthly alcohol consumption, drinks per drinking day, and self-reported alcohol craving.

The NNT context: The number needed to treat (NNT) for semaglutide was 4.3, compared to an NNT of 7 or higher for currently approved AUD medications (naltrexone, acamprosate, disulfiram). If replicated in larger trials, this would make semaglutide the most effective pharmacotherapy for AUD yet studied.

What Limits the Findings

This was a single trial of 108 participants. The study enrolled only people with comorbid obesity; whether the effect holds in patients without obesity is unknown. GLP-1 receptor agonists are not FDA-approved for AUD. A Phase 3 semaglutide trial for AUD is underway at the NIH.

Why This Matters for the Field

The GLP-1 mechanism — modulating reward and satiety signals through the mesolimbic dopamine pathway — suggests a potentially substance-agnostic approach to reducing cravings. A BMJ study of more than 600,000 US veterans found that people taking GLP-1 medications had a 14–25% lower risk of developing SUD across five substance classes.

Learn about evidence-based treatment options for alcohol use disorder through Rize.

Sources Cited

  1. 01.A
    Once-weekly semaglutide versus placebo in patients with AUD and comorbid obesityThe Lancet
  2. 02.A
    Adding weekly GLP-1 to CBT further reduces heavy drinkingNIH

Filed Under

sciencetreatmentAlcoholPeer-Reviewed ResearchClinical TrialThe Treatment Gap

Continue reading

More from this section

Science & Medicine

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.

Science & Medicine

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.

Science & Medicine

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.